Huons
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Huons makes prescription medicines, including local anaesthetics and eye drops, as well as wellness injectables such as vitamin drips and weight-management drugs.
It supplies hospitals, clinics, and pharmacies across South Korea, and also manufactures medicines on a contract basis for other domestic and international pharmaceutical companies. Listed on KOSDAQ, South Korea's tech and small-cap exchange, the company operates across three distinct segments: prescription pharmaceuticals, beauty and wellness products, and contract manufacturing.
Summary is AI-generated and may contain errors · figures from DART filings
Huons in five facts
What does Huons do?
Huons makes prescription medicines, including local anaesthetics and eye drops, as well as wellness injectables such as vitamin drips and weight-management drugs.
Where is Huons listed and in which sector?
Huons (Korean name: 휴온스) trades under KRX code 243070 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Huons?
Its market capitalisation was US$161.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Huons's latest annual revenue and operating profit?
For fiscal year 2025, Huons reported revenue of US$468.5M, operating profit of US$34.4M and net income of US$31.9M, per its annual report on DART (data retrieved from DART on 2026-09-18). Revenue was up 5.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-18
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- DisclosureOct 21
- DisclosureSep 23
- [Amended] Material event report (merger)
Huons has withdrawn, by board resolution on August 26, 2026, its May 18, 2026 decision to absorb affiliate Huons Lab Co., Ltd. (merger ratio 1:0.4256943), citing shareholder opposition from parent Huons Global's shareholders, new duplicate-listing guidelines, and a widened gap between the merger/appraisal price and the current share price amid pharma-sector volatility; all related procedures, including the extraordinary shareholders' meeting, are cancelled.
M&A · Aug 26 · 6 versions - Cash/in-kind dividend decision (quarterly dividend)
Huons declared a cash dividend of US$0.14 per share, equal to about 0.75% of the recent share price.
Dividend · Aug 11 - Operating results (consolidated) (preliminary) (fair disclosure)
Huons filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$104M (−5.8% year on year), operating profit of US$2.07M (−77.6% year on year) and a net loss of US$763K (from a profit a year earlier).
Earnings · Aug 11 - Completion report on merger, etc. (merger)M&A · Jun 26
- Cash/in-kind dividend decision
Huons declared a cash dividend of US$0.13 per share, equal to about 0.66% of the recent share price.
Dividend · May 12 - Operating results (consolidated) (preliminary) (fair disclosure)
Huons filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$95M (−2.7% year on year), an operating loss of US$435K (from a profit a year earlier) and net income of US$128K (−98.5% year on year).
Earnings · May 12 - [Attachment amended] Material event report (merger)M&A · Apr 23
- Material event report (merger)M&A · Apr 22
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Huons reported consolidated results for FY2025: revenue of US$431M (+5.2% year on year), operating profit of US$31.7M (+14.9% year on year) and net income of US$28.9M (+43.2% year on year).
Earnings · Feb 13 - Operating results (consolidated) (preliminary) (fair disclosure)
Huons filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$115M (+12.7% year on year), operating profit of US$6.83M (−10.6% year on year) and net income of US$6.4M (+135% year on year).
Earnings · Feb 13 - Cash/in-kind dividend decision
Huons declared a cash dividend of US$0.14 per share.
Dividend · Feb 13